Piramal to create screening facility to boost in-vitro biology capabilities
The move is expected to bring added value to customers by coupling biology services with existing chemistry capabilities
Piramal Pharma Solutions has made a multimillion dollar investment to create a world-class high-throughput screening facility that will augment the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India.
This new expansion, which is expected to go live in Q3 2022, will significantly add to the primary and secondary screening capabilities of compounds prepared at the Ahmedabad site.
The CDMO says that by offering integrated chemistry and biology services from a single site, customers can anticipate significant improvements to drug discovery cycle times.
The new high-throughput screening technology enables Piramal Pharma Solutions to evaluate and screen 1000 compounds per week using various assay platform technologies such as fluorescent imaging plate reader (FLIPR), time-resolved fluorescence resonance energy transfer/homogeneous time-resolved fluorescence (TR-FRET/HTRF), fluorescence polarisation (FP), absorbance, luminescence/electrochemiluminescence (ECL), alpha screen, lantha screen, flow cytometry, and high content imaging. These platforms will be applicable to a variety of targets including, for example, G-protein-coupled receptors (GPCRs) and kinase-targeted therapies.
In addition, new personnel with experience in biology services are being added to the site team, complementing the existing technical and operational expertise.
Related News
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.